最大程度经尿道电切对多机构大队列膀胱切除术后病理结果的影响
该多机构队列纳入785例接受新辅助化疗后行根治性膀胱切除术的肌层浸润性膀胱癌患者,579例(74%)接受了最大程度经尿道电切。最大程度电切与膀胱切除术后降期相关(校正OR 1.6,95%CI 1.1-2.5),但与总生存无显著关联(校正HR 0.8,95%CI 0.6-1.1)。作者认为最大程度电切可能改善病理缓解,但对长期生存的最终影响需进一步研究。
要点
- 785例肌层浸润性膀胱癌患者中,579例(74%)接受了最大程度经尿道电切。
- 最大程度电切与膀胱切除术后降期相关(校正OR 1.6,95%CI 1.1-2.5)。
- 最大程度电切与总生存无显著关联(校正HR 0.8,95%CI 0.6-1.1)。
核心结论
- 在接受新辅助化疗前经尿道电切治疗的肌层浸润性膀胱癌患者中,最大程度切除可能改善膀胱切除术时的病理缓解。
- 然而,对长期生存和肿瘤学结局的最终影响需进一步研究。
研究设计与样本
- 多机构队列研究,纳入785例接受新辅助化疗后行根治性膀胱切除术的肌层浸润性膀胱癌患者。
- 采用双变量比较和分层多变量模型量化最大程度经尿道电切对膀胱切除术时病理发现和生存的影响。
主要发现
- 785例患者中579例(74%)接受了最大程度经尿道电切。
- 不完全经尿道电切在临床肿瘤(cT)分期和淋巴结(cN)分期更晚的患者中更常见(分别为P < .001和P < .01)。
- 不完全经尿道电切与膀胱切除术时更晚的ypT分期和更高的手术切缘阳性率相关(分别为P < .01和P < .05)。
- 在多变量模型中,最大程度经尿道电切与膀胱切除术时降期相关(校正OR 1.6,95%CI 1.1-2.5)。
- 在Cox比例风险分析中,最大程度经尿道电切与总生存无显著关联(校正HR 0.8,95%CI 0.6-1.1)。
临床怎么用
- 作者认为,对于新辅助化疗前接受经尿道电切的肌层浸润性膀胱癌患者,最大程度切除可能改善膀胱切除术时的病理缓解。
- 作者指出,最大程度切除对长期生存和肿瘤学结局的最终影响需进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: While the presence of residual disease at the time of radical cystectomy for bladder cancer is an established prognostic indicator, controversy remains regarding the importance of maximal transurethral resection prior to neoadjuvant chemotherapy. We characterized the influence of maximal transurethral resection on pathological and survival outcomes using a large, multi-institutional cohort. MATERIALS AND METHODS: We identified 785 patients from a multi-institutional cohort undergoing radical cystectomy for muscle-invasive bladder cancer after neoadjuvant chemotherapy. We employed bivariate comparisons and stratified multivariable models to quantify the effect of maximal transurethral resection on pathological findings at cystectomy and survival. RESULTS: Of 785 patients, 579 (74%) underwent maximal transurethral resection. Incomplete transurethral resection was more frequent in patients with more advanced clinical tumor (cT) and nodal (cN) stage (P < .001 and P < .01, respectively), with more advanced ypT stage at cystectomy and higher rates of positive surgical margins (P < .01 and P < .05, respectively). In multivariable models, maximal transurethral resection was associated with downstaging at cystectomy (adjusted odds ratio 1.6, 95% CI 1.1-2.5). In Cox proportional hazards analysis, maximal transurethral resection was not associated with overall survival (adjusted HR 0.8, 95% CI 0.6-1.1). CONCLUSIONS: In patients undergoing transurethral resection for muscle-invasive bladder cancer prior to neoadjuvant chemotherapy, maximal resection may improve pathological response at cystectomy. However, the ultimate effects on long-term survival and oncologic outcomes warrant further investigation.
引用
- Kirk PS, Lotan Y, Zargar H, et al. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. J Urol. 2023. PMID: 36795962. doi:10.1097/JU.0000000000003193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。